According to the head of the National Institutes of Health, Francis Collins, independent researchers study the results of clinical trials of the vaccine for safety and effectiveness.
The United States authorities may register a vaccine against the new coronavirus from AstraZeneca in an expedited manner for emergency use in a month if the results of its clinical trials are positive. This was stated by the head of the National Institutes of Health (under the Department of Health and Human Services), Francis Collins, to Reuters on Monday.
According to him, independent researchers are currently studying the results of clinical trials of a vaccine produced by the British-Swedish company AstraZeneca and the University of Oxford with the participation of 30 thousand people in the United States for safety and effectiveness. If the studies’ results are successful, then, as explained by Collins, the Food and Drug Administration can complete its analysis in about a month and register the AstraZeneca vaccine for emergency use on an expedited basis.
The US authorities have already approved the use of the coronavirus vaccine by Johnson & Johnson, Moderna, as well as Pfizer, and BioNTech in the country.
Earlier, some countries suspended the use of the AstraZeneca vaccine.